Washington – The nation’s first vaccine against bird flu is only modestly effective, producing apparent protection in slightly over half the people who receive two mega-dose shots, initial testing shows. The worrisome findings underscore the urgency of brewing a better vaccine.
The government had signaled that this vaccine had serious flaws even as it ordered $162 million worth of shots last summer to stockpile in case the bird flu mutated to spread easily from person to person.
But results of the first human testing, published in today’s New England Journal of Medicine, show the extent of the problem: The vaccine sparked a protective immune response in disappointingly few people – 54 percent of those who got two shots, 28 days apart, of the highest dose.
Regular winter flu shots, in contrast, protect 75 percent to 90 percent of young healthy people, the same group that first tested the experimental bird-flu vaccine.
The elderly typically fare worse; how they respond to the bird-flu shots still is being analyzed.
The results weren’t surprising, said lead researcher Dr. John Treanor of the University of Rochester. Humans have never been exposed to the deadly bird-flu strain called H5N1, and it takes the immune system a while to ramp up to fight unique types of influenza.
The good news: The vaccine seems safe even at doses 12 times as strong as are used in the regular winter flu shot. The main side effect was pain at the site of the injection.
Researchers are giving the study’s 451 volunteers a third dose, to see if that spurs more protection.
More promising are other studies underway that add immune-enhancing chemicals to the shots to try to boost their power, in hopes people could be protected with lower doses.
“We have a long way to go,” acknowledged Dr. Anthony Fauci, infectious-disease chief at the National Institutes of Health, which funded the research.
